BCRX
Price
$8.39
Change
+$0.18 (+2.19%)
Updated
Apr 25, 04:59 PM (EDT)
Capitalization
1.72B
6 days until earnings call
DNLI
Price
$15.70
Change
+$0.21 (+1.36%)
Updated
Apr 25, 04:59 PM (EDT)
Capitalization
2.25B
18 days until earnings call
Ad is loading...

BCRX vs DNLI

Header iconBCRX vs DNLI Comparison
Open Charts BCRX vs DNLIBanner chart's image
BioCryst Pharmaceuticals
Price$8.39
Change+$0.18 (+2.19%)
Volume$25.81K
Capitalization1.72B
Denali Therapeutics
Price$15.70
Change+$0.21 (+1.36%)
Volume$19.81K
Capitalization2.25B
BCRX vs DNLI Comparison Chart
Loading...
BCRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
DNLI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
BCRX vs. DNLI commentary
Apr 26, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BCRX is a Buy and DNLI is a Buy.

Ad is loading...
COMPARISON
Comparison
Apr 26, 2025
Stock price -- (BCRX: $8.22 vs. DNLI: $15.49)
Brand notoriety: BCRX: Notable vs. DNLI: Not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BCRX: 89% vs. DNLI: 94%
Market capitalization -- BCRX: $1.72B vs. DNLI: $2.25B
BCRX [@Biotechnology] is valued at $1.72B. DNLI’s [@Biotechnology] market capitalization is $2.25B. The market cap for tickers in the [@Biotechnology] industry ranges from $275.91B to $0. The average market capitalization across the [@Biotechnology] industry is $2.16B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BCRX’s FA Score shows that 1 FA rating(s) are green whileDNLI’s FA Score has 0 green FA rating(s).

  • BCRX’s FA Score: 1 green, 4 red.
  • DNLI’s FA Score: 0 green, 5 red.
According to our system of comparison, BCRX is a better buy in the long-term than DNLI.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BCRX’s TA Score shows that 6 TA indicator(s) are bullish while DNLI’s TA Score has 4 bullish TA indicator(s).

  • BCRX’s TA Score: 6 bullish, 3 bearish.
  • DNLI’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, BCRX is a better buy in the short-term than DNLI.

Price Growth

BCRX (@Biotechnology) experienced а +11.08% price change this week, while DNLI (@Biotechnology) price change was +21.59% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.20%. For the same industry, the average monthly price growth was -4.19%, and the average quarterly price growth was -12.04%.

Reported Earning Dates

BCRX is expected to report earnings on Jul 31, 2025.

DNLI is expected to report earnings on Jul 31, 2025.

Industries' Descriptions

@Biotechnology (+7.20% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
DNLI($2.25B) has a higher market cap than BCRX($1.72B). BCRX YTD gains are higher at: 9.309 vs. DNLI (-23.994). BCRX has higher annual earnings (EBITDA): 12.8M vs. DNLI (-492.89M). DNLI has more cash in the bank: 832M vs. BCRX (321M). DNLI has less debt than BCRX: DNLI (48.7M) vs BCRX (809M). BCRX has higher revenues than DNLI: BCRX (451M) vs DNLI (0).
BCRXDNLIBCRX / DNLI
Capitalization1.72B2.25B76%
EBITDA12.8M-492.89M-3%
Gain YTD9.309-23.994-39%
P/E RatioN/AN/A-
Revenue451M0-
Total Cash321M832M39%
Total Debt809M48.7M1,661%
FUNDAMENTALS RATINGS
BCRX vs DNLI: Fundamental Ratings
BCRX
DNLI
OUTLOOK RATING
1..100
2417
VALUATION
overvalued / fair valued / undervalued
1..100
31
Undervalued
94
Overvalued
PROFIT vs RISK RATING
1..100
65100
SMR RATING
1..100
10039
PRICE GROWTH RATING
1..100
4264
P/E GROWTH RATING
1..100
10098
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

BCRX's Valuation (31) in the Biotechnology industry is somewhat better than the same rating for DNLI (94). This means that BCRX’s stock grew somewhat faster than DNLI’s over the last 12 months.

BCRX's Profit vs Risk Rating (65) in the Biotechnology industry is somewhat better than the same rating for DNLI (100). This means that BCRX’s stock grew somewhat faster than DNLI’s over the last 12 months.

DNLI's SMR Rating (39) in the Biotechnology industry is somewhat better than the same rating for BCRX (100). This means that DNLI’s stock grew somewhat faster than BCRX’s over the last 12 months.

BCRX's Price Growth Rating (42) in the Biotechnology industry is in the same range as DNLI (64). This means that BCRX’s stock grew similarly to DNLI’s over the last 12 months.

DNLI's P/E Growth Rating (98) in the Biotechnology industry is in the same range as BCRX (100). This means that DNLI’s stock grew similarly to BCRX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BCRXDNLI
RSI
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
88%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 2 days ago
88%
Momentum
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
78%
MACD
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
80%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
79%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
76%
Advances
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
78%
Declines
ODDS (%)
Bearish Trend 18 days ago
80%
Bearish Trend 10 days ago
80%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
83%
Bearish Trend 2 days ago
76%
Aroon
ODDS (%)
Bearish Trend 2 days ago
82%
Bearish Trend 2 days ago
83%
View a ticker or compare two or three
Ad is loading...
BCRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
DNLI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
RGBLX36.970.47
+1.29%
American Funds Global Balanced R1
FIRTX9.35N/A
N/A
Fidelity Advisor Intl Real Estate M
AHSCX11.07N/A
N/A
Alger Health Sciences C
IVOAX16.95N/A
N/A
Macquarie Mid Cap Income Opps A
MXPBX11.27N/A
N/A
Empower International Index Instl

BCRX and

Correlation & Price change

A.I.dvisor indicates that over the last year, BCRX has been loosely correlated with VCYT. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if BCRX jumps, then VCYT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BCRX
1D Price
Change %
BCRX100%
+3.27%
VCYT - BCRX
46%
Loosely correlated
+2.15%
OCGN - BCRX
44%
Loosely correlated
+2.78%
ETNB - BCRX
38%
Loosely correlated
+4.23%
DNLI - BCRX
38%
Loosely correlated
+4.17%
ARWR - BCRX
38%
Loosely correlated
+2.54%
More